Association between bisphenol exposure and polycystic ovary syndrome risk: an integrated systematic review and meta-analysis - Top-Institutions - MDSpire

Association between bisphenol exposure and polycystic ovary syndrome risk: an integrated systematic review and meta-analysis

  • By

  • Zongying Gui

  • Huizhen Lin

  • Chuhan Wang

  • Yingsha Yao

  • June 11, 2026

  • 0 min

Share

Top Institutions in Obgyn

Brief introduction explaining scope and methodology.

  • #1

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, Massachusetts

    Key Differentiators

    • Reproductive Endocrinology
    • Obstetrics & Gynecology

  • #2

    University of California, San Francisco
    University of California, San Francisco

    San Francisco, California

    Key Differentiators

    • Reproductive Endocrinology
    • Obstetrics & Gynecology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Epidemiology
    • Biostatistics

  • #4

    UK Biobank
    UK Biobank

    Stockport, England

    Key Differentiators

    • Epidemiology
    • Public Health

  • #5

    University of Naples Federico II
    University of Naples Federico II

    Naples, Italy

    Key Differentiators

    • Reproductive Endocrinology

Original Source(s)

Association between bisphenol exposure and polycystic ovary syndrome risk: an integrated systematic review and meta-analysis

  • by Zongying Gui, Huizhen Lin, Chuhan Wang, Yingsha Yao

  • June 11, 2026

Related Content

Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case–control study

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.